The Emerging Technologies and Therapeutics Reports provide timely summaries of evidence supporting new drugs, devices, and other healthcare technologies that are recently in use or may be available in the near term in the United States. The documents also identify gaps that need to be addressed for the technologies or therapeutics to move forward.
Narrative Review and Evidence Mapping of Artificial Intelligence in Clinical Care
From self-driving cars to smart supply chains, artificial intelligence (AI) has already changed many aspects of human life. Some areas of health care, such as medical imaging, are benefiting from AI, but questions remain on the role of AI in the broader health sector. Recognizing the importance of this emerging technology and the potential of AI to improve health for all, this report focuses on applications of AI in health that are currently in use or may be in use in the near future.
This four-page document spotlights information from the Narrative Review and Evidence Map on Artificial Intelligence (AI) in Clinical Care. The issue brief describes AI applications currently in use and on the horizon, evidence for AI in clinical medicine, and challenges and opportunities ahead.
Narrative Review and Evidence Mapping of Proteomics for Cancer and Cardiovascular Disease
Clinical proteomics offers the promise of more precise risk assessment, diagnosis, and prognosis of disease. Proteomic testing has been proposed for a wide variety of applications and conditions. This report offers a narrative review and evidence maps for proteomics for cancer and cardiovascular disease.
Landscape Review and Evidence Map of Gene Therapy
Gene therapy has evolved rapidly and may be poised to affect mainstream medicine. Gene therapy initially targeted incurable genetic diseases (e.g., metabolic diseases), but indications have now expanded, and now the most commonly used applications are to treat certain cancers. In response to the increase in approved gene therapy approaches, PCORI commissioned this landscape review. The purpose of this report is to better understand the evidence supporting currently approved gene therapies and those that may be available in the near term in the United States. Because the literature base across all of the interventions is so large, we split the content into 2 parts.
Part I: Adenovirus, Adeno-Associated Virus, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
Part I of the report focuses on adenovirus, adeno-associated virus vector-based (AAV) gene therapy, and clustered regularly interspaced short palindromic repeats (CRISPR). It addresses the description of the interventions, the context in which gene therapy is used, ongoing premarket and postmarket gene therapy studies, and current evidence for the use of gene therapy.
Part II: Chimeric Antigen Receptor-T cell (CAR-T), Autologous Cell, Antisense, RNA Interference (RNAi), Zinc Finger Nuclease (ZFN), Genetically Modified Oncolytic Herpes Virus
Part II of the report focuses on chimeric antigen receptor T cell (CAR-T); autologous cell; zinc finger nuclease (ZFN); antisense; ribonucleic acid interference (RNAi); and oncolytic viral therapy replication-competent, attenuated derivative of herpes simplex virus type 1 therapies.
This four-page document spotlights information from the Landscape Review and Evidence Map of Gene Therapy. The issue brief discusses approved therapies and those on the horizon, as well as the challenges and opportunities ahead.
B-cell Lymphoma and Non-Hodgkin’s Lymphoma Treatment: How Do Participants of Chimeric Antigen Receptor T-cell Therapy Research Studies Compare With Patients in the US Population?
Human gene therapy has evolved rapidly, and chimeric antigen receptor T-cell (CAR-T) therapy appears to be a promising treatment for B-cell lymphoma and non-Hodgkin’s lymphoma. This report compares participants of CAR-T therapy research studies to individuals living with the diseases in the US population.
Posted: June 11, 2019; Updated: February 9, 2021